Reproductive Medicine Center, Department of Gynecology and Obstetrics, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi, China.
Clinical Research Center for Reproductive Medicine and Gynecological Endocrine Diseases of Shaanxi Province, Xi'an, Shaanxi, China.
Front Endocrinol (Lausanne). 2023 Jul 6;14:1183209. doi: 10.3389/fendo.2023.1183209. eCollection 2023.
This meta-analysis aims to evaluate the efficacy and safety of autologous platelet-rich plasma (PRP) administration in reducing adhesion recurrence and improving pregnancy outcomes in patients with intrauterine adhesion (IUA).
We conducted a comprehensive search of Pubmed, Embase, the Cochrane Library, Web of Science, Scopus, and China National Knowledge Internet (CNKI) from inception to February 10, 2023, without any language or regional restrictions. We used random-effects models to assess odds ratios (OR) and weight mean differences (WMD) with 95% confidence intervals (CI).
Our meta-analysis included a total of 730 patients from 10 clinical studies (6 RCTs and 4 non-RCTs). The results showed that PRP administration significantly increased endometrial thickness (WMD = 0.79, 95% CI: 0.40-1.19; P < 0.001; I = 0.0%), menstrual volume (WMD = 2.96, 95% CI = 2.30-3.61; P < 0.001; I = 0.0%), and days of menstruation (WMD = 1.13, 95% CI = 0.86-1.41; P < 0.001; I = 0.0%). Additionally, the clinical pregnancy rate was also improved (OR = 1.82, 95% CI: 1.19-2.78; P = 0.006; I = 0.0%). However, there was insufficient evidence to reach a conclusion regarding the effects of PRP on the recurrence rate of moderate to severe IUA, changes in AFS scores, miscarriage rate, and live birth rate.
Our analysis confirms that autologous PRP is an effective treatment for IUA. However, the limited sample size suggests that the results should be interpreted with caution. Therefore, larger and well-designed studies are necessary in the future to confirm these findings and explore the optimal PRP dosing regimens further.
https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023391115.
本荟萃分析旨在评估自体富血小板血浆(PRP)给药在降低宫腔粘连(IUA)患者粘连复发率和改善妊娠结局方面的疗效和安全性。
我们对 Pubmed、Embase、Cochrane 图书馆、Web of Science、Scopus 和中国国家知识基础设施(CNKI)进行了全面检索,检索时间从建库至 2023 年 2 月 10 日,无语言或地区限制。我们使用随机效应模型评估优势比(OR)和加权均数差(WMD)及其 95%置信区间(CI)。
我们的荟萃分析共纳入了 10 项临床研究(6 项 RCT 和 4 项非 RCT)的 730 名患者。结果表明,PRP 给药可显著增加子宫内膜厚度(WMD=0.79,95%CI:0.40-1.19;P<0.001;I=0.0%)、月经量(WMD=2.96,95%CI=2.30-3.61;P<0.001;I=0.0%)和经期天数(WMD=1.13,95%CI=0.86-1.41;P<0.001;I=0.0%)。此外,临床妊娠率也得到了改善(OR=1.82,95%CI:1.19-2.78;P=0.006;I=0.0%)。然而,关于 PRP 对中重度 IUA 复发率、AFS 评分变化、流产率和活产率的影响,尚无足够证据得出结论。
本分析证实,自体 PRP 是治疗 IUA 的有效方法。但是,样本量有限,因此结果应谨慎解释。因此,未来需要更大和设计良好的研究来进一步证实这些发现并探索最佳的 PRP 剂量方案。
https://www.crd.york.ac.uk/PROSPERO,标识符 CRD42023391115。